Immunotherapy for prostate cancer works by helping a patient’s own immune system fight back against cancer cells.

For men with high or very-high risk prostate cancer (extraprostatic extension or into seminal vesicles, pelvic regional lymph nodes, biopsy showing Grade Group 4 or 5 [Gleason 8-10], PSA >20 ng/mL) local curative intent therapies with surgery or radiation may not be able to eliminate already escaped/metastatic prostate cancer cells.

Johns Hopkins is leading a multi-center, national, randomized study of an immunotherapy with promising immune system activity [building on an earlier study: Nature Medicine and Johns Hopkins Medicine] towards possibly eliminating any escaped prostate cancer cells thereby potentially increasing the chance of cure with surgery. More information at https://www.clinicaltrials.gov/study/NCT06014255.

Common side effects of the HEAT trial immunotherapy include fever, fatigue, chills, back and joint pain, headache and nausea. They are associated with the infusion period and usually only last for a few days.

Please setup an appointment today to see if you are eligible for the HEAT trial.